Jun 18 |
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
|
Apr 16 |
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
|
Apr 10 |
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
|
Apr 1 |
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
|
Mar 28 |
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript
|
Mar 18 |
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
|
Mar 18 |
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
|
Mar 11 |
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
|
Mar 8 |
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
|
Feb 26 |
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
|